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La fragilité héréditaire des nerfs périphériques à la compression 
Une étude électrophysiologique et génétique 
 
 
 
La fragilité héréditaire des nerfs périphériques à la compression, ou hereditary neuropathy 
with liability to pressure palsies (HNPP), a été décrite pour la première fois par De Jong en 1947 et 
dans la littérature anglo-saxone par Davies en 1954. C’est une neuropathie héréditaire chronique 
caractérisée par des épisodes récidivants de paralysie avec paresthésies. La prévalence des 
neuropathies héréditaires motrices et sensorielles (hereditary motor and sensory neuropathy HMNS) 
est estimée à 1 pour 10000 (Nelis et al., 1996). 
 
L’HNPP se manifeste à tous les âges, le début des symptômes étant le plus souvent reconnu 
durant la deuxième et troisième décennie. Bien que les deux sexes puissent être concernés, on note 
une légère prédominance masculine, probablement liée à une exposition accrue aux risques 
professionnels (Meier et Moll, 1982). 
 
La clinique est variable, les patients pouvant se présenter avec une attaque de paralysie 
franche ou alternativement de manière plus insidieuse. L’éventail des symptômes comprend des 
paresthésies et engourdissements de courte durée jusqu’à des paralysies chroniques.  L’examen 
clinique peut révéler des réflexes tendineux diminués ou absents dans les régions concernées (Meier et 
Moll, 1982). L’évolution de l’affection est le plus souvent favorable bien qu’une progression plus 
sévère soit également décrite. Il est important que les sujets atteints comprennent leur neuropathie et 
puissent ainsi prendre des mesures préventives afin d’éviter les facteurs déclenchants. La 
décompression chirurgicale peut parfois améliorer sinon éliminer la symptomatologie (Roth et 
Magistris, 1984). 
 
L’évènement qui déclenche les attaques est en général un traumatisme, une traction ou une 
compression d’un nerf périphérique. Certaines positions prolongées suffisent parfois à déclencher les 
symptômes. Parfois aucun processus initial ne peut être trouvé lors de l’anamnèse. 
 
Les caractéristiques électrophysiologiques de l’HNPP ont été établies en grande partie par 
Earl et al. en 1964. On note un ralentissement des vitesses de conduction nerveuses et une réduction 
d’amplitude des potentiels d’actions globaux moteurs et sensitifs des nerfs atteints cliniquement. Les 
anomalies électrophysiologiques peuvent concerner des nerfs non atteints cliniquement ainsi que des 
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membres asymptomatiques de la famille. Le ralentissement des vitesses de conduction est plus 
prononcé aux sites d’enclavements ainsi que dans les segments distaux des nerfs (Behse et al, 1972). 
Des signes de régénération axonale avec des réflexes d’axones moteurs sont également observés 
(Roth 1978, Magistris et Roth, 1985). Des blocs de conduction expliquent les épisodes de paralysie; 
ils sont parfois persistants (Magistris et Roth, 1985). 
 
Histologiquement l’HNPP présente des épaississements localisés de la myéline. Décrits pour 
la première fois par Behse en 1972, ces épaississements ont été appelés “tomacula” par Madrid et 
Bradley en 1975. Bien que les épaississements de la myeline ne soient pas spécifiques de l’HNPP, 
leur présence en grand nombre l’est. L’amyotrophie est rare ou tardive dans l’HNPP. 
 
Le diagnostic différentiel se fait principalement parmi les neuropathies héréditaires, dont 
l'amyotrophie hérédo-familiale du plexus brachial et le syndrome de Charcot-Marie-Tooth (CMT1A) 
sont des exemples. 
 
L’HNPP est transmise sur un mode autosomique dominant. La recherche génétique a depuis 
quelques années apporté de nombreux développements dans la compréhension de cette neuropathie. 
L’anomalie génétique la plus souvent mise en cause est une délétion de 1.5 mégabases sur le bras 
court du chromosome 17. C’est une région du chromosome qui contient le gène PMP-22 (Peripheral 
Myelin Protein 22) (Chance et al, 1993; Mariman et al, 1993). Le locus de ce gène a été impliqué tout 
d’abord en utilisant des techniques de “linkage analysis” mais des mutations ponctuelles de quelques 
paires de bases dans l’exon 1 de ce gène ont par la suite confirmé son importance dans la pathogénie 
de la maladie (Nicholson et al, 1994). Des mutations ponctuelles ont depuis été mises en évidence 
chez des sujets qui ne présentaient pas la délétion 17p11.2 complète. Depuis ces découvertes initiales, 
des études cliniques et génétiques ont confirmé que la délétion 17p11.2 est l’anomalie génétique la 
plus courante chez les patients présentant des anomalies de conduction nerveuse et des présentations 
cliniques typiques et se trouve chez 85% des patients (Gouider et al, 1995, Tyson et al, 1996). 
D’autres auteurs ont suggéré qu’il existe une hétérogénéité génétique de l’HNPP (Mariman et al, 
1994). 
 
Le rôle exact de la protéine PMP-22 n’est pas connu. Des études montrent que la protéine est 
présente dans la myéline compacte et suggèrent qu’elle n’est pas seulement une protéine structurale 
mais qu’elle serait également un canal ou un pore non-spécifique (Suter et al, 1993). L’expression 
anormale du mRNA, et donc de la protéine, a été proposée comme étant le facteur déterminant dans la 
pathogénie moléculaire d’une série de maladies dont la maladie de Charcot-Marie-Tooth 1A, celle de 
Déjerine-Sottas et l’HNPP (Yoshikawa et al, 1994). En tout état de cause il est démontré que 
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l’expression correcte de la protéine PMP-22 est essentielle à la myélinisation normale (Trapp et al, 
1996; Murakami et al, 1996). 
 
La région 17p11.2 de 1.5 Mb de l’HNPP est précisément celle qui présente une duplication 
dans la maladie de Charcot-Marie-Tooth Type 1A (Valentijn et al, 1992). Ceci constitue le premier 
exemple humain d’un syndrome résultant de produits réciproques d’échanges inégaux de segments 
intra-chromosomiques, et en particulier de crossover inégaux survenant durant la méiose (Chance et 
al, 1994). D’autres mécanismes qui pourraient produire la délétion ont été proposés. Le Guern et al, 
1996, ont suggéré que la délétion pouvait être le résultat de réarrangements intra-chromosomiques 
dans des cas de novo d’origine maternelle. Il est remarquable que le résultat de la duplication soit 
similaire à celui de la délétion puisque la CMT fait partie du diagnostic différentiel de l’HNPP (Roth 
et Magistris, 1984). 
 
Au vu de l’hétérogénéité, cette recherche vise à vérifier si les patients suivis dans l'unité 
d'électroneuromyographie et des affections neuromusculaires de la clinique de Neurologie de 
l’Hôpital Cantonal, pour une HNPP basé sur des observations cliniques et électrophysiologiques, sont 
porteur de la délétion 17p11.2. Vingt quatre individus appartenant à 23 familles on été étudiés. 
Quatres domaines cliniques, soit l'anamnèse personnelle et familiale, les observations cliniques et 
l'étude électrophysiologique, ont été utilisés pour déterminer une probabilité d’HNPP, et chaque 
individu inclu dans l’étude a été classé dans un groupe de faible, moyenne, ou forte probabilité. Ceci a 
été comparé au résultat génétique. La technique du Fluorescent in situ hybridisation (FISH) et le 
Southern blotting quantitatif sont celles qui ont été utilisées pour l’analyse génétique. La délétion 
17p11.p a été trouvée chez 7 individus appartenant à 6 familles. Parmi ces individus, 4 étaient 
fortement suspects de présenter une HNPP. Dans une famille, 2 des 3 membres étudiés présentaient la 
délétion. Pris séparément, les différents composants du score proposé sont mal corrélés avec les 
résultats génétiques. En score composé par contre, la corrélation est bonne, la délétion ayant été 
retrouvée chez tous les sujets présentant une forte probabilité. 
 
Un individu présentant a) une neuropathie transmise sur un mode autosomale dominante, b) 
avec des plaintes de parésie et paresthésies chroniques et récurrentes à mettre en relation avec des 
traumatismes mineurs, c) et chez qui l'étude électrophysiologique montre un ralentissement des 
vitesses de conduction nerveuses et des blocs de conduction, a une grande probabilité d'être atteint de 
l'HNPP. La délétion 17p11.2 est spécifique de l'HNPP et permet donc comme une confirmation du 
diagnostique. 
 
Aujourd’hui, diverses techniques de biologie moléculaire permettent de détecter la délétion 
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17p11.2, qui constitue l’anomalie génétique la plus fréquente de l’HNPP. Au vu de la diversité de la 
génétique de l’HNPP, les techniques qui ne détectent que la délétion n’excluent pas des mutations 
ponctuelles dans le gène PMP-22; seules les techniques qui permettent une évaluation directe de la 
séquence d’ADN peuvent exclure toute anomalie. 
 
Il n'y a pas de traitement de l'HNPP mais la confirmation du diagnostic est en soi souvent 
importante pour le patient et permet la mise en œuvre de moyens de prévention simples. Nous 
disposons aujourd'hui d'un test moléculaire qui allie efficacité à des coûts acceptables, qui permet une 
confirmation diagnostique rapide. Les tests génétiques sont particulièrement utiles chez les individus 
ayant une présentation clinique et électrophysiologique atypique. La confirmation du diagnostic 
génétique permet un conseil génétique pour l'individu et les membres de sa famille. Les sujets atteints 
doivent éviter des mouvements, postures ou situations favorisant le traumatisme d'un nerf. Cette étude 
ne permet pas de conclure à une possible hétérogénéité génétique de l'HNPP mais elle établit une base 
pour procéder à des tests plus approfondis avec recherche de mutations du gène PMP22. 
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1.0 Summary 
 1.1 Abstract 
 
 Hereditary neuropathy with liability to pressure palsies (HNPP) is a chronic peripheral nerve 
disorder. Individuals typically present chronic and recurrent complaints of palsies with paraesthesiae 
related to minor trauma. Electrophysiological studies show nerve conduction slowings and conduction 
blocks, usually more marked at entrapment sites. Schwann cell swellings ("tomacula") are morphological 
changes of peripheral nerves characteristic of HNPP. A 1.5 Mb deletion on chromosome 17p11.2 is 
considered specific of HNPP and serves as definite confirmation of the diagnosis. The implicated gene is 
PMP22, which codes for a peripheral myelin protein. This research aims to determine whether patients 
currently being followed for symptoms and complaints consistent with HNPP and having 
electrophysiological studies suggestive of HNPP, actually have the implicated deletion. The individuals 
enrolled in this study were those being followed by the ENMG unit of the HUG Neurology Clinic. 
Twenty-four subjects from 22 families were studied. The individuals’ clinical and electrophysiological 
findings were used to determine their respective clinical probability of having HNPP. Four areas of 
particular value were used for the proposed clinical scoring system, namely personal and family 
history, clinical and electrophysiological findings. The main diagnostic technique used to detect the 1.5 
Mb PMP22 deletion on chromosome 17 was fluorescent in situ hybridisation (FISH). The deletion was 
found in 7 of the 24 individuals studied. Of these 7 patients, 4 were highly suspected of having HNPP 
on the basis of the clinical and electrophysiological findings. The deletion was found in 3 individuals 
in whom HNPP was not strongly suspected, and notably in one whose findings suggested a low 
probability. In one family, of the 3 members investigated, 2 had the deletion. Personal and family 
history, and clinical findings, taken individually, were poorly correlated with the genetic results. 
Taken together as composite score however, the deletion was found in all the patients with a high 
probability. Although there is presently no curative treatment for this neuropathy, providing a diagnosis to 
patients is of interest since simple preventive measures to avoid nerve trauma can greatly reduce the 
potential disability associated with HNPP. With the advent of modern molecular analysis, rapid and 
effective diagnosis is becoming a reality. Genetic testing is of particular interest in patients with an 
atypical clinical and electrophysiological presentation. Confirming the presence of the genetic defect has 
implications for the individual as well as for family members, allowing for preventive measures and 
genetic counselling. Our results do not provide a conclusive answer to the question of a possible genetic 
heterogeneity. This study lays the groundwork for further investigations to be carried out. In particular 
direct sequence analysis could provide interesting insights into the disease and its presentation. 
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 1.2 Résumé 
 
La fragilité héréditaire des nerfs périphériques à la compression (HNPP) est une neuropathie 
périphérique chronique caractérisée par des épisodes récidivants de paralysie avec paresthésies. 
L'événement qui déclenche les attaques est en général un traumatisme ou la compression d'un nerf. 
Les études électrophysiologiques montrent un ralentissement des vitesses de conduction nerveuses, 
ainsi que des blocs de conduction, prédominants aux lieux d'enclavements. A l'histologie, l’HNPP 
présente des épaississements localisés de la myéline appelés “tomacula”. L’HNPP est transmise sur un 
mode autosomique dominant. L’anomalie génétique la plus souvent mise en cause est une délétion de 
1.5 mégabases sur le bras court du chromosome 17. C’est une région du chromosome qui contient le 
gène PMP22 qui code pour une protéine de la myéline périphérique. Au vu de l’hétérogénéité de 
présentation, cette étude a visé à vérifier si les patients suivis par la Clinique de Neurologie de 
l’Hôpital Cantonal pour une HNPP suspectée sur les observations cliniques et électrophysiologiques, 
sont porteurs de la délétion 17p11.2. Vingt-quatre individus appartenant à 22 familles ont été étudiés. 
Quatre domaines, soit l'anamnèse personnelle et familiale, les trouvailles cliniques et l'étude 
électrophysiologique, ont été utilisés pour déterminer une probabilité d’HNPP, et chaque individu 
inclus dans l’étude a été classé dans un groupe de faible, moyenne, ou forte probabilité. Ceci a été 
comparé au résultat génétique. La Fluorescent in situ hybridisation (FISH) est la technique 
principalement utilisée pour l’analyse génétique. La délétion 17p11. a été trouvée chez 7 individus 
appartenant à 6 familles. Parmi ces individus, 4 étaient fortement suspect de présenter une HNPP. La 
délétion a également été trouvée chez 2 individus chez qui la suspicion était respectivement moyenne 
et faible. Dans une famille, 2 des 3 membres étudiés présentaient la délétion. Pris séparément, les 
composants du score proposé sont mal corrélés avec les résultats génétiques. En score composé par 
contre, la corrélation est bonne, la délétion ayant été retrouvée chez tout les sujets présentant une forte 
probabilité. Il n'y a pas de traitement de l'HNPP mais la confirmation du diagnostic est en soi souvent 
importante pour le patient et permet la mise en œuvre de moyens de prévention simples. Nous 
disposons aujourd'hui d'un test moléculaire qui permet une confirmation diagnostique rapide. Les tests 
génétiques sont particulièrement utiles chez les individus ayant une présentation clinique et 
électrophysiologique atypique. La confirmation du diagnostic génétique permet un conseil génétique 
pour l'individu et les membres de sa famille. Cette étude ne permet pas de conclure concernant une 
possible hétérogénéité génétique de l'HNPP mais elle établit une base pour procéder à des tests plus 
approfondis avec recherche de mutations du gène PMP22. 
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2.0 Introduction
 
 2.1 Historical background, clinical presentation and evolution
 
 Hereditary neuropathy with liability to pressure palsies (HNPP) is a chronic peripheral nerve 
disorder characterised by acute and often recurrent palsies with paraesthesiae. The earliest descriptions of 
the condition were made by De Jong in 1947, and by Davies in 1954. These authors reported several cases 
in families with recurrent peripheral nerve palsies. Wahle and Tönnis first used the term HNPP in 1958. 
Since then the disorder has been progressively better characterized. The prevalence of hereditary motor 
and sensory neuropathies (HMSN), of which HNPP constitutes an unclear proportion, is estimated at 1 in 
10000 (Nelis et al., 1996). 
 
 The onset of HNPP can occur at any age, but the disorder often starts during the second to 
third decade of life. HNPP affects both males and females, but there is a slightly higher incidence in 
males; this may be due to their greater exposure to occupational hazards (Meier and Moll, 1982). The 
clinical presentation of HNPP varies; it sometimes presents in a dramatic manner with outright 
paralysis or alternatively appears rather insidiously. Symptoms range from short-lived paraesthesiae 
and numbness, to chronic paralysis. Fasciculations and myokymias in certain muscle groups have also 
been described as presenting symptoms (Andreadou et al., 1995). Clinical examination sometimes 
reveals decreased or absent deep tendon reflexes in given areas (Meier and Moll, 1982; Serratrice et 
al., 1987). Severe and incapacitating evolution of the disease has been described, but is rare (Barbieri 
et al., 1990). Pain is unusual but when present it usually involves the brachial plexus (Meier and Moll, 
1982). 
 
 The triggering event to HNPP is generally trivial and seemingly minor trauma, traction or 
compression of a particular peripheral nerve. In some instances no initiating process can be found. 
Typically the prolonged exposure of some nerves to certain positions may suffice to produce 
symptoms (Meier and Moll, 1982). The brachial plexus, for example, can be injured whilst lying on 
one side, sleeping with an arm above the head, or carrying a heavy weight. Sitting with crossed legs 
can imply the common peroneal nerve. Nerves are especially susceptible at entrapment sites; the ulnar 
nerve at the elbow is a common example of this. Other sites in the upper limb include the median 
nerve in the carpal tunnel, the ulnar nerve in the Guyon canal, and the radial nerve when it enters the 
anterior region of the arm. In the lower limb the most common impairment is the common peroneal 
nerve at the head of the fibula. In their review, Meier and Moll analysed 290 attacks in 93 patients and 
showed that the peroneal and ulnar nerves were the most frequently involved, being affected in 35% 
and 20% of the cases respectively (Meier and Moll, 1984, Figure 1). 
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Figure 1 Analysis of 290 nerve palsies in 93 patients (taken from well documented attacks in literature and 
from investigated series). Reproduced from Meier and Moll, 1982. 
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Figure 2 Age distribution of index cases of 40 HNPP families (80 patients). Reproduced from Meier and Moll, 
1982. 
 
 The evolution of HNPP is extremely varied. Earl et al. (1964) in their study of four families 
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showed that most incidents involving palsies are followed by recovery, occasionally incomplete. Roth and 
Magistris (1984) reported cases of unremitting palsies that lasted for years. The progression of the disease 
is closely linked to the manner in which patients adapt to the condition. Presently the best course of action 
is for a patient to understand and therefore avoid movements, postures or situations that act as triggering 
factors. In some cases surgical decompression of nerves, or neurolysis, has proved effective in alleviating 
or eliminating symptoms (Roth and Magistris, 1984). 
 
 
 2.2 Electrophysiological aspects
 
 
 The electrophysiological findings in HNPP have been comprehensively established. Earl et al. 
(1964) were the first to publish a systematic study of the problem. They showed that there is a general 
slowing of nerve conduction velocities and a reduction of the amplitude of the compound motor and 
sensory action potentials in clinically affected nerves. It is interesting to note that electrophysiological 
abnormalities are also found in clinically unaffected nerves, as well as in asymptomatic members of 
families with HNPP. Other particularities that have been reported involve slowing of conduction 
velocities, especially at entrapment sites and in distal segments of nerves, and the fact that sensory nerve 
fibres are more consistently affected than motor nerve fibres (Behse et al., 1972). In 1985 Magistris and 
Roth published a report of long lasting conduction blocks found in patients with HNPP. The multiplicity 
and chronicity of the blocks at entrapment sites was considered characteristic. A total of 38 patients were 
examined and extensive electrophysiological investigations were carried out. Roth was the first to describe 
conduction blocks of long duration that were directly related to this particular disease (Roth, 1978). Since 
then other conditions leading to persistent conduction blocks have been defined: Multifocal Sensory 
Motor Neuropathy (Lewis et al., 1982), Multifocal Motor Neuropathy (Roth et al., 1986), and nerve 
lesions that follow radiotherapy (Roth et al., 1988). 
 
 Interestingly, electrophysiological studies have shown that motor axon reflexes (MAR) are found 
in patients with HNPP. MARs are electrophysiological responses found when damaged peripheral axons 
regenerate and give birth to more than one axonal extension. Motor axon reflex potentials are 
electrophysiological responses that have distinctive characteristics. The observed presence of MARs at 
first electrophysiological examination demonstrates that the neuropathy in HNPP brings about chronic and 
long lasting axonal regeneration (Roth, 1978; Roth and Magistris, 1984; Magistris and Roth, 1985). 
 
 2.3 Pathology and histological aspects
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 Morphological changes are often found in HNPP, and nerve biopsies are particularly 
revealing. Behse et al. (1972) were the first to describe local thickenings of the myelin sheath around 
axonal fibres whilst studying the sural nerve. These Schwann cell swellings were termed “tomacula”, 
from the latin word for sausage, by Madrid and Bradley (1975). Taking into account this histological 
characteristic, the term “tomaculous neuropathy” is used by certain authors to designate this 
condition. The focal swellings of the nerve fibres consist of an excessive number of abnormally 
folded myelin lamellae. Behse et al. (1972) in their initial work, showed that the swellings consisted 
of over 500 myelin lamellae, whereas normal nerve samples have between 90 and 200. Most authors 
who have found and described tomacula have used a method known as “teasing”, whereby single 
fibres are isolated and then examined individually (Behse et al., 1972). Oda et al. (1990) showed that 
the tomacula tended to line up on certain axons instead of being distributed randomly. These authors 
suggested that this finding indicates that, in addition to the genetically determined generalized 
myelination disorder, some signals emanating from the axons might play a role in the formation of 
tomacula. Focal thickening of myelin is not specific to HNPP and has been observed in neuropathies 
such as Charcot-Marie-Tooth disease and Dejerine−Sottas disease (Pouget et al., 1992). Nevertheless 
it is only in HNPP that tomacula are found in such abundance (Pouget et al., 1992). Behse et al. 
(1972), for example, counted 1 per 200-300 nerve fibres in random cross−section cuts, and showed 
that one fourth of the internodal segments in their study contained portions in which the diameter was 
increased to as much as twice that of the remaining segment. The swellings were located in both nodal 
and paranodal segments. Within these areas the axonal diameter is reduced and Behse et al. (1972) 
suggested that this change in the axonal to myelin ratio could account for some of the slowing of 
conduction velocities. 
 
 Several mechanisms have been proposed for the formation of tomacula (Behse et al., 1972; 
Meier and Moll, 1982). One theory holds that they are a result of hypermyelination with excessive 
numbers of myelin lamellae being deposited in a periodic fashion around the axon. However, 
tomacula most frequently seem to result from an abnormal folding of the myelin lamellae; the 
formation of redundant loops with secondary wrapping of double-folded loops around the axon 
creating asymmetric thickening of the myelin sheath. 
 
 Other findings such as focal demyelination and remyelination, loss of large myelinated fibres and 
an increase in number of small myelinated fibres have been reported (Behse et al., 1972; Meier and Moll, 
1982). In a 1984 article reporting 23 patients, Roth and Magistris suggested that the conduction blocks 
mentioned earlier could be caused by the influence of the tomacula on the nodes of Ranvier as well as by 
the frequently accompanied intussusception of one myelin segment into a neighbouring segment with 
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consecutive displacement of the node. Only a few nerve biopsies were carried out in this study because 
clinical and electrophysiological findings were considered to suffice for the diagnosis (Roth and Magistris, 
1984; Magistris and Roth, 1985). Significantly, these authors mentioned a number of instances in which 
tomacula were not found, or were rare, in clinically typical cases of HNPP; other authors have also 
reported this (Behse et al., 1972; Windebank, 1984). It has been suggested that the absence of tomacula in 
some cases indicates that the focal thickening of myelin might only be present at certain stages of the 
pathological process (Behse et al., 1972; Windebank, 1984). That tomacula have not been found in great 
numbers in all individuals with HNPP diagnosed on the basis of clinical and electrophysiological criteria 
is suggestive of an underlying genetic heterogeneity. It will be discussed later. 
 
 Amyotrophy is unusual at the time of the first episodes of HNPP (Pouget et al., 1992). With 
repeated lesions and paralysis muscle atrophy eventually occurs; certain muscle groups of the foot as 
well as those innervated by the ulnar nerve are reportedly most at risk (Pouget et al., 1992). Magistris 
and Roth (1985) have suggested that muscle atrophy is not consistently found because axoplasmic 
transport of trophic factors remains unaffected even in the presence of conduction blocks. 
A 
 
50 µm 
 
B 
 
50 µm 
 
 
Figure 3, A and B (X160 and X400 respectively) Pictures showing tomacula in myelin sheath of individual axons 
(X160). A method known as “teasing” is used to obtain the single fibres. Pictures by Dr GP Pizzolato, Unité de 
neuropathologie, département de pathologie clinique, Genève. 
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2.4 Diagnosis of HNPP 
 
 Diagnosis of HNPP requires a multidisciplinary approach. Some of the most essential diagnostic 
information comes from the family history of a patient, with, whenever possible, special importance given 
to establishing an accurate family tree. In this way an evaluation of the type of genetic transmission can be 
established even if the heterogeneity of the clinical presentation may make this difficult. The age of onset 
and precise conditions under which the symptoms present have to be determined, and the notion of 
relapsing or recurrent episodes is important. Electrophysiological studies with investigation of nerve 
conduction velocities and the search for conduction blocks are the next step. Electrophysiological studies 
of family members may be used to demonstrate that the neuropathy under study is hereditary. Nerve 
conduction studies are established using surface electrodes. Segments covering the axilla, elbow, wrist, 
knee and ankle being especially studied because these areas include entrapment sites and are therefore 
territories in which conduction blocks are most likely to be found. A nerve biopsy in search of tomacula 
on nerve cross-sections or on teased fibres is sometimes performed, but because of its invasive nature it is 
not routinely used in the work up of HNPP. 
 
 Today genetic investigations and studies confirm the diagnosis when suspected by the above and 
promise to replace part of this process. As is discussed later, the discovery of a deletion on chromosome 
17 that is causative of HNPP, and the ready availability of reliable and precise genetic tests offers a 
potential for a rapid and cheap confirmation of the diagnosis. 
 
 
 2.4.1 Differential diagnosis of HNPP and classification
 
 The differential diagnosis of HNPP includes a number of diseases, mostly within the hereditary 
neuropathies (Meier and Moll, 1982; Pouget et al., 1992). Among these is a form of mononeuritis 
multiplex, namely hereditary mononeuritis multiplex with brachial predilection, or hereditary neuralgic 
amyotrophy. This disorder has an autosomal dominant inheritance and usually occurs in females where it 
is often associated with pregnancy. It is clinically and genetically distinct (Gouider et al., 1994; Chance et 
al., 1994; Pellegrino et al., 1996). In contrast to HNPP, it is painful and leads to amyotrophy and sensory 
loss affecting mainly the brachial plexus. However, both motor and sensory conduction velocities are 
normal (Windebank, 1994; Meier and Moll, 1982). Certain recurrent mononeuropathies associated with 
vasculitis in collagen diseases or diabetes mellitus should also be considered. Electrophysiology can show 
slowing of motor and sensory conduction velocities and therefore specific laboratory tests and typical 
nerve biopsy findings are required for them to be recognised. In some cases Charcot-Marie-Tooth 1 (CMT 
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1, HMSN-I, Peroneal muscle atrophy) should be considered in the differential diagnosis. This disorder, in 
which motor deficit predominates, results from a genetic abnormality in the same area of chromosome 17 
as HNPP, a duplication rather than a deletion of the PMP 22 gene (see 3.0 Genetics and molecular 
understanding of HNPP). Histologically CMT 1 presents onion bulb formations of the myelin sheath that 
are different to the tomacula found in HNPP (see summary in Table I). 
 
 Combining previous clinical and electrophysiological observations with recent advances in the 
understanding of the molecular basis of diseases of the peripheral nervous system, several classification 
systems have been proposed. Schematically, there are two types of hereditary peripheral neuropathies: 
those affecting the axon and those affecting the Schwann cells of the myelin sheath. CMT 1 or hereditary 
motor and sensory neuropathy I (HMSN I), HNPP and Dejerine-Sottas neuropathy (DSS, HMNS III) are 
caused by abnormalities in Schwann cells and peripheral myelin (Lupski et al., 1997). CMT 2 (HMSN II), 
which can be distinguished electrophysiologically, appears to be caused by an axonal or neuronal defect 
(Murakami et al., 1996). Furthermore CMT 1 is sub classified genetically as either CMT 1A (autosomal 
dominant, usually linked to 17p11.2-p12 markers), CMT 1B (rare, linkage to 1q21.2-q23, or CMT 1C 
(autosomal dominant not linked to either chromosome 1 or 17) (Murakami et al., 1996). The other CMTs 
are also sub classified with regard to their specific genetic defects. X-linked CMT (CMT X) is associated 
with multiple mutations in the connexin 32 gene in the Xq13.1 region (Murakami et al, 1996). In males it 
presents similarly to CMT 1, whereas in females it shares certain electrophysiological traits with CMT 2. 
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Disorder Clinical Presentation Inheritance 
Pattern 
Age of 
Onset 
Electro- 
physiological 
Findings 
Histology Genetic 
Defect 
Hereditary 
neuropathy with 
liability to pressure 
palsies (HNPP) 
Chronic and recurrent 
peripheral palsies with 
paraesthesiae, 
particularly ulnar and 
peroneal nerves 
Autosomal 
dominant 
Predominantly 2nd-
3rd decades 
Slowing of nerve 
conduction, 
conduction blocks 
at entrapment sites 
Tomaculous change 
in myelin sheath 
17p11.2 (PMP22) 
deletion, PMP22 
point mutations 
Hereditary 
mononeuropathy 
multiplex with 
brachial 
predilection 
One or several peripheral 
nerves involved, 
neuralgic amyotrophy, 
sensory loss 
Autosomal 
dominant 
     Normal nerve
conduction 
velocities 
Charcot-Marie-
Tooth 1 (CMT 1A, 
HMSN I) 
Pes cavus, congenital hip 
problems, motor deficit 
predominates 
Autosomal 
dominant 
2nd-3rd decades Slowing of nerve 
conduction 
Hypertrophic 
changes with onion 
bulb formations 
17p11.2 (PMP22) 
duplication, or point 
mutations 
Mononeuropathies 
associated with 
diabetes, 
polyarteritis nodosa 
 None Variable Nerve conduction
can show slowings 
    None
Déjerine - Sottas 
neuropathy (HMNS 
III) 
Severe limb weakness Autosomal 
recessive 
1st decade Slowing of nerve 
conduction 
Onion bulb 
formations 
Homozygous 
PMP22 duplication, 
point mutations 
 
Table I Disorders to be considered in the differential diagnosis of HNPP. Findings of HNPP are listed for comparison. 
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3.0 Genetics and molecular understanding of HNPP
 
 It has been known since the earliest descriptions of HNPP that the disease is transmitted in an 
autosomal dominant manner. In part due to its variable phenotype expressivity, the exact prevalence of 
HNPP is still unknown (Murakami et al., 1996). As an overall group of diseases, CMT is the most 
common inherited disorder of the peripheral nervous system. The prevalence of all types of HMSN is 
estimated at 1 in 10000 (Nelis et al., 1996). Authors propose that the frequency of the most common 
genetic defect associated with HNPP may be similar to that of the most common defect associated with 
CMT1 (Murakami et al., 1996) (see below). The most recent step towards understanding HNPP has come 
about as a result of genetic research involving the identification of a deletion on the short arm of 
chromosome 17. The deletion covers a 1.5 megabase region that includes the gene for peripheral myelin 
protein 22 (PMP22) (Matsumi et al., 1992; Chance et al., 1993; Mariman et al., 1993). The locus for this 
gene was first implicated by linkage analysis of affected families, in particular in the study of three 
pedigrees by Chance et al. (1993), but point mutations leading to frameshifts have since been discovered 
in patients, confirming its involvement (Nicholson et al.; 1994, Young et al., 1997; Bissar-Tadmouri et al., 
2000). Clinical and genetic studies have recently showed that the 17p11.2 deletion is present in 
approximately 85% of patients with typical nerve conduction abnormalities or clinical presentations 
(Gouider et al., 1995; Tyson et al., 1996; Nelis et al., 1996). Linkage analysis and gene dosage studies 
provide some evidence of genetic heterogeneity underlying HNPP and other genes might be implicated 
(Mariman et al., 1994). Phenotypic heterogeneity in patients with different genetic mutations has also been 
described (Pareyson et al., 1996; Lenssen et al., 1998). 
 
 The PMP22 gene was first shown to be contained within the CMT 1A duplication (Timmerman 
et al., 1992). The exact role of the protein PMP22 is not known. It is an integral membrane glycoprotein. 
Studies have found it to be present principally but not exclusively in compact myelin of the peripheral 
nervous system. It is produced almost exclusively by Schwann cells (Snipes et al., 1992; Suter et al., 1993; 
Stögbauer et al., 2000). These authors suggest that it not only is a structural protein, but that it may also act 
as a channel or non-specific pore protein. The abnormal expression of the mRNA and the PMP22 protein 
has been proposed as the main determining factor in the molecular pathogenesis of a series of diseases 
including CMT 1A, DSS/HMNS III and HNPP (Yoshikawa et al., 1994; Schenone et al., 1997). It acts in 
a dose-dependent manner. Increased gene dosage leads to CMT 1A, whereas decreased gene dosage is 
found in HNPP (Stögbauer et al., 2000). In their study of mice deficient in the PMP22 gene (PMP220/0 
mice), Adlkofer et al. (1995), concluded that PMP22 is required for the correct development of peripheral 
nerves, the maintenance of axons and the determination of myelin thickness and stability. Studies on 
PMP0/0 mice or on mice carrying the trembler (Tr) mutation in the PMP22 gene (Suter et al., 1992), 
systematically show walking difficulties as a consequence of progressive paralysis (Suter et al., 1993, 
Adlkofer et al., 1995). Other studies have confirmed that the PMP22 protein and its correct expression are 
essential for normal myelination (Trapp et al., 1996; Murakami et al., 1996) and normal Schwann cell 
growth (Suter et al., 1993). 
 
 The gene region that is deleted in HNPP is duplicated in CMT 1A (Valentijn et al., 1992), and is 
the first example in humans of Mendelian syndromes resulting from the reciprocal products of unequal 
exchange involving intra-chromosomal segments, particularly unequal crossover during meiosis (Chance 
et al., 1994). It provides the basis for furthering the understanding of meiotic recombination in humans 
(Reiter et al., 1998). Remarkably, the result of the duplication is, to some extent, similar to that of the 
deletion since CMT is part of the differential diagnosis (Roth and Magistris, 1984). Other mechanisms that 
can lead to the deletion have been proposed. Le Guern et al. (1996) have suggested that the deletion can be 
the result of intrachromosomal rearrangement in de novo cases of maternal origin and that this mechanism 
may be specific to maternal transmission. 
 
 
 
Figure 4 Diagram showing relationship of proteins of myelin, including PMP22, and structure of the myelinated 
axon in the peripheral nervous system (MAG: myelin associated glycoprotein; MBP: myelin basic proteins; MDL: 
major dense line; IPL: intraperiod line; PMP22: peripheral myelin protein 22; P0: protein zero). Reproduced from 
Suter et al., 1993. 
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4.0 The investigation
 
 4.1 Aim of the investigation
 
 In light of a possible heterogeneity of presentation of HNPP patients, this research aims to 
determine whether all patients currently being followed for symptoms and complaints consistent with 
HNPP and having electrophysiological studies suggestive of HNPP, actually have the implicated deletion. 
The underlying question is therefore whether or not the clinical heterogeneity of HNPP is in fact a 
reflection of heterogeneous genetic defects. The potential benefits of the study include the advances it may 
provide with respect to our understanding of HNPP. The comparison of diagnoses made on classical 
criteria with those made on the basis of genetic investigations should give an indication of the efficiency 
and sensitivity of genetic diagnosis. The latter should prove valuable not only for symptomatic patients, 
but also for the diagnosis of asymptomatic family members. This development will allow better genetic 
counselling and preventive measures to be taken. 
 
 
 
 4.2 Methods 
 4.2.1 Study subjects and HNPP probability scoring
 
 The individuals enrolled for this study were those that are currently being followed for, or had 
already been recognised, by the ENMG unit of the HUG Neurology Clinic as probably having HNPP 
based on clinical and electrophysiological findings. Twenty-four individuals from 22 families were 
studied. The investigation protocol was accepted by the University of Geneva Hospital ethics committee 
(Cométhique) on the 21 June 1995. All individuals included were investigated before 1997. 
 
 The nature of the research required minimal patient involvement. One blood sample of 9 ml 
per patient was taken. An electroneuromyographic control was carried out on patients who had not 
undergone a thorough examination beforehand or who had an ambiguous clinical picture. All 
individuals enrolled in the study were volunteers and, when desired, received genetic counseling. 
Special emphasis was given to possible preventive measures. Where it was indicated surgery was 
suggested. 
 
 After the initial enrolment, the individuals’ clinical and electrophysiological findings were 
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used to determine their respective probability of having HNPP. Four areas of particular value were 
tentatively used for the proposed clinical scoring system, namely personal and family history, clinical 
findings, electrophysiological findings. Nerve biopsy was done in only one patient and was therefore not 
used in the overall scoring. The relevance of each of these 4 categories was assessed for every 
individual and a score assigned to them. The total score was used to establish three overall groups of 
probability. Each individual was therefore placed into a group with either a low, moderate or high 
probability of having HNPP. This probability was then compared with the genetic results, the latter 
indicating whether or not a 17p11.2 deletion was detected. It might be noted that for some individuals 
not all the relevant information was available. In other instances certain features of the work up were 
deemed to be overwhelming and a presumptive diagnosis was made on, for example, the basis of the 
strong electrophysiological data. These subjects are marked with an asterisk (*) in table III. 
 
Proposed scoring: 
 
Category Scoring for each category 
(indication of HNPP) 
Overall probability for each 
subject 
Personal history 0 = atypical or not done ≤ 6 = low 
Family history 1 = low 7 – 9 = moderate 
Clinical findings 2 = moderate ≥ 10 = high 
Electrophysiological findings 3 = high  
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 4.2.2 Overview of the techniques
 
 The main diagnostic technique used to detect the 1.5 Kb 17p11.2 deletion on chromosome 17 was 
fluorescent in situ hybridisation (FISH). This is a method whereby lymphocytes from heparinized blood 
are cultured in vitro. The lymphocytes are then fixed and transferred to slides. Cloned PMP22 gene probes 
are used to locate or confirm the absence of the concerned gene. The probe is associated with a fluorescent 
marker that enables direct microscopic analysis. This is the technique that was used in Geneva under the 
supervision of Dr Michael Morris (Laboratoire de Diagnostic Moléculaire, Division de Génétique 
Médicale, HUG). Twenty-one blood samples were tested using this method. Initially, and whilst the FISH 
was being developed in Geneva, some samples were tested using quantitative Southern blotting. In this 
technique, genomic DNA is cut with restriction enzymes and the resultant fragments are separated by size 
on a gel. After transfer onto a filter, a specific probe consisting of cloned cDNA is used to locate the 
desired gene or DNA segment. The gene copy number is estimated by quantification of the 
autoradiograph. This technique was used on 7 blood samples by Professor J. M. Burgunder (Laboratoire 
de Neuromorphologie, Clinique et Policlinique de Neurologie, Inselspital de Bern). 
 
 
 4.2.3 An introduction to fluorescent in situ hybridisation (FISH) 
 
 In situ hybridization can be used with several forms of genetic substrate, namely repetitive, 
single copy or cosmid probes and chromosome-specific libraries. It allows specific nucleic acid 
sequences to be detected in morphologically preserved chromosomes or in interphase nuclei. The 
technique was developed by Pardue and Gall (1969) and by John et al. (1969). Because molecular 
cloning was not initially available, this type of hybridisation could only be applied to genomic 
sequences that could be obtained and isolated using conventional methods. The radio labeling of the 
probes had the inconveniences associated with the handling of radioactive material. Specific 
oligonucleotide probes are now available and non-radioactive markers are used. Two nonradioactive 
hybridization methods can be distinguished, namely the direct and indirect procedures. In the direct 
method the detectable molecule (reporter) is bound directly to the nucleic acid probe so that formed 
hybrids can be visualized microscopically immediately after hybridisation with the target nucleic acid. 
The technique used in this study was an indirect procedure in which the probe contains a reporter 
molecule introduced chemically or enzymatically that renders it detectable by affinity cytochemistry. 
The reporter molecule has to be accessible to antibodies so that the full accuracy of this method is 
preserved. To optimize the precision and reliability of the results a two-colour in situ hybridisation 
procedure was used. This required the use of two reporter molecules, digoxigenin (DIG) and biotin. 
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Digoxigenin is isolated from digitalis plants, namely Digitalis purpurea and Digitalis lanata. The 
blossoms and leaves of these plants are the only natural source of Digoxigenin and therefore no 
binding of the anti-DIG antibodies occurs in other biological material. The digoxigenin probes were 
revealed with fluorescein or FITC (Fluoresceinisothiocyanate) labelled antibodies, giving a green 
signal. The other molecule used was biotin, a vitamin of the B complex. Although the biotin probes 
could be detected using anti-biotin antibodies, in this case avidin was used. Avidin is a glycoprotein 
found in egg white and is used because of its high binding capacity with biotin. Coupled with 
rhodamine, this complex gives a red signal. Before incorporation into the probes both digoxigenin and 
biotin were linked to uridine (or deoxyuridine) nucleotides at the number 5 position. Boehringer 
Mannheim Biochemica, 1996. 
 
 
 4.2.4 Summary of the FISH procedure used in the study
 
 For the two colour in situ hybridisation procedure two probes consisting of DNA sequences 
of chromosome 17 (17p11.2) included in the 1.5 Mb deletion of the PMP22 gene were used. The 
probes were cl03B11 and cl32G8. They were labelled with the reporter molecules using nick 
translation, whereby digoxigenin and biotin are linked to uridine nucleotides at the number 5 position 
of the pyrimidine ring, and incorporated enzymatically into the DNA probe. The two enzymes used 
were DNase I, which is an endonuclease, and DNA polymerase I. As RNA inhibits the polymerase, 
RNase is used to eliminate any residual RNA. EDTA is added in order to chelate Mg2+ and to arrest 
the enzyme activity. Heparinized blood obtained from the subjects was cultured for three days in a RPMI 
1640 culture medium with phytohemaglutinine and gentamycine, and then treated with colchicin to arrest 
lymphocytes in metaphase. After exposure to a hypotonic solution and fixation with a methanol/acetic 
acid solution, the suspensions were “dropped” onto clean slides, which were then briefly rinsed with acetic 
acid to remove residual cytoplasm. A “mixture” (Herring sperm DNA, yeast tRNA, human Cot-1 DNA, 
the labelled probe) then underwent pre-annealing or chromosomal in situ suppression (a process by which 
introns and non relevant probe DNA are hybridised prior to exposure to the sample to be tested so that 
they do not interfere with the specificity of the procedure; the Herring sperm and Cot-1 DNA bind with 
the these sequences). After the denaturing of the fixated chromosomes (done by immersing the slides in a 
formamide/SSC (sodium citrate solution)), the slides were placed in an ethanol solution to prevent 
reassociation, and let to dehydrate. The hybridisation mixture was then placed on the prepared slides. Post 
hybridization steps included several washes and detection of the hybridized digoxigenin and biotin probes 
with high affinity fluorescein (FITC) labelled anti-digoxigenin antibodies and rhodamine labelled avidin, 
respectively. FITC appears as green, and rhodamine appears as red. High power microscopic analysis was 
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performed to visualise the chromosomes and to verify whether hybridization had occurred (Gos, 1993). 
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5.0 Results
 The following tables summarize the relevant information and findings for each individual that 
was included in this study. Table II displays the clinical information available, as well as the results of the 
genetic tests that were carried out. Table III displays the interpretation and systematic scoring of the 
different categories described in the previous chapter. Each individual was assigned to a group that 
indicates with what probability, low, moderate or high, HNPP was suspected. In some cases an 
individual was placed into a high probability group, even though all information was not available; in 
other instances certain features of the work up were deemed to be overwhelming and a presumptive 
diagnosis was made on, for example, the basis of the strong electrophysiological data. These cases are 
marked with an asterisk (*) in table III. Figure 6 summarizes the number of individuals in each 
probability category found to have a deletion. 
 
 5.2.1 Clinical and laboratory data
 
 FISH  both Southern blotting 
 
  3 4 1 
 
 
 
 
 
 
 The 17p11.2 deletion was found in 7 of the 24 individuals studied; six of these were found 
using the FISH technique and one with the Southern blotting. Where both diagnostic techniques were 
used (4 cases), the results correlated perfectly. Of the individuals presenting with the deletion, 4 were 
highly suspected of having HNPP on the basis of the clinical and electrophysiological findings. The 
deletion was found in 2 patients in whom suspicion of HNPP was moderate, and in one whose 
findings suggested a low probability. In one family, of the 3 members investigated, 2 had the deletion. 
 
 
5.1 Overview
24 individuals 21 families with 1 individual 
1 family with 3 individuals 
7 with a deletion 17 with no deletion 
Subject 
Year of birth, 
age at time of 
testing 
Sex Family History Genetics 
   
Clinical findings and results of 
biopsies if carried out 
Electrophysiological findings and 
or conclusions 
 FISH Sb 
1    1933,
62 years 
F One-month history of weakness in 
right hand following right upper limb 
immobilisation after surgery for rotator 
cuff tear. No amyotrophy. Important 
hypothenar weakness. Hypoesthesia in 
fingers. 
Right ulnar nerve conduction block 
at elbow. Sensory impairement of 
right radial nerve (low size 
potential, slowing of conduction 
velocity). Carpal tunnel syndrome. 
Incomplete family 
history. 
Del Not
done 
2   1972,
23 years 
M Following ski accident, 1-month 
history of parasthesiae on ulnar side 
and two last fingers of right hand. 
History of repeated spasmodic 
torticollis. 
Right ulnar nerve conduction block 
at elbow. Sensory and motor fibre 
involvement predominantly 15 mm 
above medial epicondyle.  
No relevant family 
history.  
No 
Del 
No 
Del 
3  1947,
28 years 
F Motor and sensory deficit in left ulnar 
nerve after compression at the elbow. 
Status post bilateral carpal tunnel 
syndrome. 2-3 history of burning type 
sensation in right thigh area. 
Left ulnar nerve 60% conduction 
block at elbow in sulcus nervi 
ulnaris, focal slowing of conduction 
velocity. Several affected nerves 
with conduction blocks at 
entrapment sites. 
No clear family notion 
of neurological 
problems. 
No 
Del 
Not 
done 
4  1939,
57 years 
F Patient investigated for right foot drop, 
evolving over several years with 
progressive worsening. Bilateral carpal 
tunnel syndrome. Sensory and motor 
deficits in right lower limb, bilateral 
achillean areflexia. 
Sensory and motor deficit of 
peripheral nervous system. Mainly 
axonal impairment, few signs of 
acute denervation, some signs of 
chronic de- and reinervation (large 
motor unit potentials). No 
predominance of affection at 
entrapment sites. 
Incomplete family 
history 
No 
Del 
Not 
done 
5  1979,
17 years 
M Right foot drop, which appeared after a 
hike, with no other apparent cause. No 
associated pain. First episode. Total 
deficit of muscles of anterior 
compartment of lower leg, 
hypoesthesia on dorsum of foot. 
Mixed affection of common 
peroneal nerve at the neck of fibula, 
with 50% axonotmesis and 50% 
neurapraxia. 
No family history of 
neurological problems. 
No 
Del 
Not 
done 
6  1917,
78 years 
F Decreased proximal strength in lower 
limbs with history of fatigability. 
Sensory, motor and autonomic 
polyneuropathy prevailing in lower 
No relevant family 
history. 
No 
Del 
Not 
done 
FISH: fluorescent in situ hybridization, Sb: Southern blotting, Del: deletion detected, No Del: no deletion detected 20
Subject 
Year of birth, 
age at time of 
testing 
Sex Family History Genetics 
   
Clinical findings and results of 
biopsies if carried out 
Electrophysiological findings and 
or conclusions 
 FISH Sb 
History on non-insulin-dependant 
diabetes mellitus. History of numbness 
and paraesthesia in feet and to a lesser 
extent in 4 and 5 right fingers. 
Autonomic disturbances. Muscle 
biopsy: slight muscular damage, 
compatible with diabetic neuropathy. 
limbs. Moderate slowing of 
conduction velocity of median 
nerves at carpal tunnel bilaterally 
and of right ulnar nerve at wrist. No 
focal slowing, no conduction blocks. 
7  1990,
6 years 
F Young girl with scoliosis and areflexia 
in all four limbs. 
Diffuse myelinic type motor 
neuropathy, possibly CMT1. 
No family history of 
neuromuscular 
disorders. 
No 
Del 
Not 
done 
8    1928,
67 years 
M Neuropathy with HNPP type 
characteristics. Nerve biopsy done. 
Multifocal conduction blocks. No family history 
available. 
Del Not
done 
9  1952,
42 years 
M 6 week history of pain in right external 
sub-clavicular region and right 
shoulder blade area, radiating to 
thumb, accompanied by dysesthesia. 
Moderate right triceps amyotrophy and 
weakness. History of numbness in 
upper limbs after wind surfing. History 
of rapid onset and painless proximal 
left upper limb paralysis 7 years 
earlier, with improvement over a 2 
months period. Bilateral carpal tunnel 
syndrome. 
At time of prior upper limb 
paralysis, conduction block found 
on axillary nerve as well as 
confirmation of bilateral carpal 
tunnel syndrome. No conduction 
blocks at latest examination. 
No known neurological 
problem in parents. 
Sister operated for 
carpal tunnel syndrome. 
No 
Del 
Not 
done 
10  1955,
39 years 
M One-month history of weakness in 
right foot extensor muscles. No 
amyotrophy. Discrete sensory deficits 
on dorsum of foot. 
Principally a neurapraxic type 
impairment of right common 
peroneal nerve, with 85% 
conduction block at the neck of the 
fibula. No abnormality of ulnar 
nerve at elbow. 
No family history of 
neuromuscular 
problems. 
Not 
done 
No 
Del 
11  1923,
61 years 
M Four year history of left L4 sciatica 
with lower limb hyperreflexia and right 
foot extensor paresis (narrow lumbar 
Multineuropathy with chronic and 
“ancient” signs. No polyneuropathy. 
Bilateral slowing of ulnar nerve 
No HNPP type history 
in parents or in the rest 
of the family. 
Not 
done 
Del 
FISH: fluorescent in situ hybridization, Sb: Southern blotting, Del: deletion detected, No Del: no deletion detected 21
Subject 
Year of birth, 
age at time of 
testing 
Sex Family History Genetics 
   
Clinical findings and results of 
biopsies if carried out 
Electrophysiological findings and 
or conclusions 
 FISH Sb 
canal on MRI). Two-year history of 
bilateral ulnar nerve territory 
hypoesthesia and paresthesia in fingers. 
Left ulnar nerve appears thickened on 
palpation. Left bicipital and right 
tricipital hyporeflexia. 
conduction velocity predominating 
in sensory fibres. No conduction 
abnormality at elbow. Signs of acute 
and chronic denervation in lower 
limbs. No conduction blocks. 
12  1993,
17 months 
F Child treated with harness for left hip 
dislocation between 2 and 6 months of 
age. Symmetrical bilateral lower limb 
flaccid paralysis observed 2 weeks 
after end of treatment, with seemingly 
intact sensory function. 
Motor neurography showing very 
reduced evoked potential amplitude. 
Normal sensory neurography. 
Indicative of peripheral nerve 
impairment which only concerns 
motor fibres. 
Incomplete family 
history. 
No 
Del 
Not 
done 
13  1961,
34 years 
F Two months history of left hand 
sensory deficit and clumsiness, noticed 
on waking up one morning. Clinically, 
moderate motor and sensory deficits in 
left ulnar nerve territory. History of left 
common peroneal nerve affection, with 
rapid complete recovery. 
65% conduction block of left ulnar 
nerve localized at elbow in groove 
for ulnar nerve, with slowing of 
conduction velocity. Normal 
sensory function of median, radial 
and ulnar nerves. In 1981, left 
common peroneal nerve conduction 
block demonstrated at neck of 
fibula. 
Incomplete family 
history. 
No 
Del 
Not 
done 
14 
family A 
1945, 
49 years 
M Several weeks' history of left thenar 
area hypoesthesia; occurred after 
carrying shopping bag (compression by 
bag handle). History of many similar 
events, all regressing after some time. 
Cannot remain seated in same position 
for extended period of time without 
having paraesthesia and cramps. 
Repeated paraesthesia and cold 
sensation in hand since childhood. 
Carpal tunnel syndrome surgery in 
1987, at age 42. 
Predominantly myelinic sensory and 
motor polyneuropathy with slowing 
of conduction velocities at 
entrapment sites. Motor
neurography shows low amplitude 
evoked potentials. Conduction block 
at right elbow. Prior exam showed 
median nerve conduction block 
between wrist and palm. 
 
Many similar episodes 
in son (N°17). Brother 
undergone neurosurgical 
interventions. Sister 
hospitalised with a 
“myopathy”. Father had 
left lower limb 
“neurological problem” 
Uncle hospitalised for 
paralysis following 
discal hernia surgery. 
Del  Del
FISH: fluorescent in situ hybridization, Sb: Southern blotting, Del: deletion detected, No Del: no deletion detected 22
Subject 
Year of birth, 
age at time of 
testing 
Sex Family History Genetics 
   
Clinical findings and results of 
biopsies if carried out 
Electrophysiological findings and 
or conclusions 
 FISH Sb 
15 
family A 
1971, 
24 years 
F Sister of N°15. No complaints or 
history of neurological problems. 
Slight tendency to have paraesthesiae 
or certain sensations in lower limbs if 
remains in same position too long, for 
example at the cinema. Raynaud’s 
phenomenon has been evoked. Normal 
strength and no sensory problems. 
Electrophysiological results within 
normal limits. 
Strong family history of 
neurological problems. 
For brother see N°17, 
for father see N°15. 
Uncle and great uncle 
had neurological 
problems. 
No 
Del 
No 
Del 
16 
family A 
1967, 
26 years 
M Son of N°15. Two-month history of 
left foot drop, with no known 
triggering factor or event. Sensory 
problems on antero-external part of 
lower leg and foot. Had significant 
weight loss (10 Kg). This is first 
significant episode but has had 
previous trouble with maintaining 
certain positions such as crossed legs. 
Myelinic predominant sensory and 
motor polyneuropathy. Common 
peroneal nerve conduction block at 
the neck of fibula. 
Strong family history of 
neurological problems. 
Father has had many 
similar episodes (see 
N°15). Uncle and great 
uncle have had 
neurological problems. 
Del  Del
17   1960,
35 years 
F Neuropathy with HNPP type 
characteristics. Incomplete information 
Incomplete information Incomplete information. No 
Del 
Not 
done 
18  1945,
49 years 
M Several month history of sensory 
problems in hands on waking, with 
complaints of paresthesia and 
numbness (started in left hand). Pain in 
forearm musculature when exercising. 
Occasionally similar symptoms in toes. 
Sensory and motor conduction 
abnormalities of median nerves, 
mainly distally suggesting myelinic 
type impairment. No conduction 
blocks detected on tested nerves. No 
signs of reinnervation (no MARs ). 
Family history of 
rhumatology problems 
(arthritis in sisters). No 
history of neurological 
problems. 
Not 
done 
No 
Del 
19  1970,
16 years 
F Pain in upper right shoulder area. 
Status post surgery for shoulder 
instability following car accident in 
1992 (5 years prior to present exam). 
Three-month history of decreased 
sensation in right thumb. History of 
frequent distal hypoesthesia and 
paraesthesia in right hand on waking. 
Moderate bilateral carpal tunnel 
syndrome (subnormal bilateral 
motor latencies and subnormal right 
sensory conduction velocity). 
Incomplete family 
history. 
No 
Del 
Not 
done 
FISH: fluorescent in situ hybridization, Sb: Southern blotting, Del: deletion detected, No Del: no deletion detected 23
Subject 
Year of birth, 
age at time of 
testing 
Sex Family History Genetics 
   
Clinical findings and results of 
biopsies if carried out 
Electrophysiological findings and 
or conclusions 
 FISH Sb 
20    1928,
71 years 
F Right foot drop since 1963, following 
delivery. Fluctuating bilateral sensory 
and motor problems. Patient has 
noticed fasciculations in certain 
muscles. Neurolysis of right median 
nerve at wrist and right ulnar nerve at 
elbow in 1994 with good evolution. 
Nerve biopsies show tomacula. 
Myelinic and axonal sensory and 
motor polyneuropathy with
conduction blocks. Right ulnar 
nerve conduction block at elbow > 
50%. Sensory neurography of right 
ulnar and median nerves shows 
small amplitude responses. 
 
Incomplete family 
history. 
Del Not
done 
21  1923,
72 years 
M Chronic polyneuropathy suggestive of 
CMT1 or HNPP. 
Incomplete information. Incomplete family 
history. 
No 
Del 
Not 
done 
22    1941,
53 years 
F History of recurrent truncular nerve 
impairments. Ulnar nerve impairment 
following unusual type of work. 
Diffuse slowing of nerve conduction 
velocities, but predominating at 
entrapment sites. Persistent ulnar 
nerve conduction block at elbow 
(following unusual work). 
Family history of similar 
recurrent nerve 
impairments. 
Del Not
done 
23   1930,
64 years 
M Bilateral lumbar-sacral radiculo-
plexopathy since 1989 with global 
weakness, though predominantly in left 
lower limb. Both lower limbs affected 
in 1994. Aggravation in 1995. 
Axonal type sensory and motor 
peripheral nerve impairment of 
lower limbs. Bilateral ulnar nerve 
conduction blocks at elbows with 
axonal type neuropathy. Slight 
bilateral slowing of distal median 
nerve conduction velocities. 
No relevant family 
history. 
No 
Del 
Not 
done 
24   1981,
15 years 
M Patient with cystic fibrosis. 
Symmetrical lower limb weakness 
following pulmonary transplant 9 
months earlier. Diminished sensory 
function below knees. 
Lower limb results compatible with 
a severe axonal type sensory and 
motor neuropathy. 
Incomplete family 
history. 
No 
Del 
Not 
done 
 
Table II Summary of the clinical and electrophysiological findings and genetic results 
 
FISH: fluorescent in situ hybridization, Sb: Southern blotting, Del: deletion detected, No Del: no deletion detected 24
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Subjects  Personal 
history 
Clinical 
findings 
Family 
history 
Electrophys- 
iological 
findings 
Total 
X/12 
Probability Deletion 
1*       2 2 0 3 7 High Yes
2        2 1 0 3 6 Low No
3       3 1 0 3 7 Moderate No
4       2 2 0 3 7 Moderate No
5*        2 2 0 1 5 Low No
6        2 1 0 2 5 Low No
7        1 1 0 1 3 Low No
8       2 2 0 3 7 Moderate Yes
9        1 2 1 2 6 Low No
10       3 2 0 3 8 Moderate No
11        2 2 0 2 6 Low Yes
12        1 2 0 1 4 Low No
13       3 2 0 3 8 Moderate No
14        3 3 3 3 12 High Yes
15        2 1 3 0 6 Low No
16        3 2 3 2 10 High Yes
17*        2 2 0 0 4 Low No
18        3 2 0 1 6 Low No
19        1 2 0 2 5 Low No
20       3 3 0 3 9 Moderate Yes
21*        3 0 0 2 5 Low No
22        3 2 3 3 11 High Yes
23       2 2 0 3 7 Moderate No
24        2 2 0 1 5 Low No
* Indicates individuals on whom there is incomplete information, but with certain important characteristics in given categories. 
 
Table III Probability of HNPP, according to proposed scoring (low ≤ 6, moderate 7-9, high ≥ 10). 
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Figure 5 Age distribution of the 24 individuals included in the study (age at time of genetic testing). 
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Figure 6 Graph showing the number of patients in each probability category and the number of patients in that 
category in whom the 17p11.2 deletion was detected. 
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 5.2.2 Laboratory (FISH) data
 
 The key findings obtained with the FISH are described below. The lymphocytes are blocked in 
metaphase. Figure 7 shows FISH results for individuals with no 17p11.2 deletion; both probes can be seen 
on both chromosomes 17. Figures 8 and 9 show positive results that are cases in which the analysed 
lymphocyte chromosomes present a deletion on chromosome 17. As labelled on the figures, two cosmids 
are visible: Cosmid 1 corresponds to the cl03B11/DIG probe and is revealed with the green fluorescein 
(FITC) coupled antibodies. Cosmid 2 corresponds to the cl32G8/biotin probe and is revealed with the red 
avidin/rhodamine complex. Each probe generates two signals per chromosome, one on each chromatid. In 
figures 8 and 9 the two visible chromosomes 17 show different patterns: on one chromosome 17, both 
cosmids are visible, on the other neither cosmid can be seen, the absence of hybridised probes 
demonstrating that there is a deletion. In some pictures a third marker is present on each chromosome 17. 
This marker corresponds to a probe that binds to the tip of chromosome 17 in an area not concerned by the 
typical deletion. It is used as a control to indicate that hybridisation has occurred and facilitates the 
identification of the chromosomes 17. Without this marker, conventional morphological traits are 
necessary to identify the chromosomes. The fact that chromosomes are being blocked in metaphase of 
mitosis means that both chromatids are not yet separated. Figure 8 is the result obtained for subject 9 and 
figure 9 that for subject 1. 
 
 FISH can also be used to detect the CMT 1A type 17p11.2 duplication. An example of this 
duplication is shown in figure 10. In this case there are three pairs of PMP22 probes, but only two control 
probes, indicating that one homologous chromosome 17 has a duplicated region. In this case the 
lymphocyte nucleus is blocked in interphase. 
 
  
 
Figure 7 FISH result of a control case showing no 17p11.2 deletion. Both PMP22 probes are visible on both 
chromosomes 17. Note the presence of the control probe on both chromosomes. 
 
 
Figure 8 FISH analysis of patient 9 showing a hemizygous deletion on one of the chromosomes 17. Both PMP22 
probes are visible on one of the chromosomes but are absent on the other. 
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Figure 9 FISH result of subject 1. Hemizygous deletion. In this instance no control probe was used to identify the 
chromosomes. Arrows identify chromosomes 17. 
 
 
 
 
 
Figure 10 Fish analysis of a patient with CMT 1a. There are three pairs of PMP22 probes but only two control 
probes. The lymphocyte nucleus is blocked in interphase. 
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6.0 Discussion 
 
 Individuals presenting with: a) an autosomal dominant neuropathy, b) chronic and recurrent 
complaints of palsies and parasthesiae which can be put into relation to minor trauma, and c) in whom 
electrophysiological studies show nerve conduction velocity slowing and conduction block, have a strong 
likelihood of having HNPP. A 1.5 Mb deletion on chromosome 17p11.2 is considered specific to HNPP 
and therefore serves as a definite confirmation of the diagnosis. The deletion may also be found in 
asymptomatic individuals and family members, and molecular genetic analysis is of value for detecting at-
risk individuals. 
 
 Twenty-four individuals with suspected HNPP were included in this study. The 17p11.2 deletion 
was found in 7 of the 24 individuals studied. The probability score used was shown to give reasonably 
accurate predictions of HNPP diagnosis; all four individuals who were in the high probability group had 
the 17p11.2 deletion. It is notable that deletions were detected in two individuals in whom the suspicion 
was moderate, and in one whose suspicion of HNPP was low. Personal and family history, clinical and 
electrophysiological findings, taken individually, were poorly correlated with the genetic results. 
However, taken as a composite score there was a better correlation. Based on electrophysiological 
findings only, of the 7 individuals found to have a deletion, 5 had a high, and 2 had a moderate 
probability. A deletion was not found in 6 cases where the electrophysiological examination showed 
typical signs. This indicates that although the value of genetic testing is clear it is also true that some 
conventional findings are sensitive parameters in the diagnostic process. In some instances only genetic 
testing can formally exclude the disease. For example, in instances where some members of a family are 
affected, definite results can be very useful in identifying asymptomatic family members. Genetic results 
can be used to reassure the individual or, if positive, to provide counselling on preventive measures to be 
taken. Only genetic testing is of true value in presymptomatic patients, and is obtained by a single test for 
life. The comparison of pre-test scoring and genetic results on a greater number of subjects, including 
asymtomatic family members, in a double blinded protocol could provide useful information for the 
elaboration of a more accurate scoring tool, or to determine subgroups of individuals in whom genetic 
testing might be particularly useful. 
 
 This study supports, on a small scale, what other authors (Gouider et al., 1995; Tyson et al., 1996) 
have described, namely that the 17p11.2 deletion is the principal genetic defect found in HNPP. FISH 
provides a precise method for detecting specific defects but it can only detect abnormalities that are 
defined by the particular sequences coded by the chosen probes. In this study the fact that the deletion was 
not found in all potential cases suggests the possibility of smaller defects such as point mutations, 
examples of which can be found in the literature (Nicholson et al., 1994; Young et al., 1997; Bissar-
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Tadmouri et al., 2000). 
 
 The precise aetiology of HNPP remains unknown. The disorder is thought to result from the 
abnormal expression of a gene coding for the PMP22 protein, which is normally found in compact myelin. 
The under expression of this protein may affect not only the structure of myelin but the actual function of 
Schwann cells (Suter et al., 1993; Schenone et al., 1997). The fact that in individuals presenting with the 
1.5 Mb deletion on chromosome 17, an intact copy of the segment exists on the homologous chromosome 
might also explain some of the heterogeneity of the disorder. A dose response mechanism where by the 
quantity of PMP22 produced is the determining factor in the clinical presentation has been suggested. A 
functional polymorphism of the remaining copy of the gene could also lead to heterogeneity. PMP22 is an 
integral membrane glycoprotein and it is therefore conceivable that mutations in the gene lead to either the 
total absence of the protein or to an abnormal function. Some authors have suggested that some 
heterozygous mutations might lead to the formation of mutant proteins that hinders the proper function of 
the remaining half normal PMP22 protein, or alternatively that certain transmembrane domains are altered 
(Pareyson et al., 1997). Insights into PMP22 protein function might be obtained from precise phenotype-
genotype comparisons of specific mutations. 
 
 The limitations of FISH probably mean that, although this technique is efficient for detecting the 
deletion, it is mainly useful in confirming the diagnosis of HNPP. When no deletion is detected, the 
possibility - however slight - of point mutations or other defects cannot be excluded. Carrying out direct 
sequence analysis is perhaps the only way to completely understand the genetic defects found in 
individuals with HNPP. However, according to present literature and the overwhelming importance of the 
1.5 Mb deletion in most affected individuals (Nelis et al., 1996), as well as the relatively high cost, this is 
probably not justified in a routine clinical workup. 
 
 In spite of its limitations, FISH presents many advantages. It is, comparatively, a simple 
technique, which allows for rapid results and is relatively inexpensive, making it a useful and potent 
clinical tool. 
 
 Hereditary neuropathy with liability to pressure palsies is a disorder that has been known to exist 
for fifty years. It is a condition with a variable clinical expression. Although there is no curative treatment 
for this neuropathy, being able to provide patients with a diagnosis is often in itself an important step. The 
condition is one in which simple preventive measures to avoid nerve trauma can greatly reduce the 
potential disability associated with HNPP. 
 
 With the advent of modern molecular analysis, rapid and effective diagnosis is becoming a 
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reality. Although a thorough history, physical exam and complete electrophysiological exam still form the 
basis of the diagnosis, genetic testing can now offer a significant aid. It is of particular interest in patients 
with an atypical clinical and electrophysiological presentation. Confirming the presence of the genetic 
defect has implications for the individual as well as for other family members. Genetic counselling is an 
essential part of the care and management of patients. FISH provides an efficient way of obtaining ready 
confirmation of the diagnosis, and therefore has the potential to become a valid clinical tool. It is 
important to understand that FISH is useful principally when it provides a positive result; when negative 
results are obtained, possible point mutations or other disorders affecting the expression of PMP22 cannot 
be excluded. 
 
 One of the aims of this study was to verify whether or not the diverse clinical presentation of 
HNPP is a reflection of a genetic heterogeneity. Although the results do not provide a conclusive answer, 
the fact that, in this study, the deletion was not detected in all patients who had a high probability of 
having the disorder, lays the groundwork for further investigations to be carried out. In particular direct 
sequence analysis could provide interesting insights into the disease and its presentation. 
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7.0 Annexes
 
Fluorescent in situ hybridisation: For Hybridisation with Cosmid Probes. 
Arnaud Gos, Laboratoire de Diagnostic Moléculaire, Division de Génétique Médicale 
 
I) Probe labelling 
Mix in an eppendorf tube: 
- 2 µg DNA 
- 10 µl 10 * nick translation buffer (0.5 M Tris/HCl, 50 mM MgCl2, 0.5 mg/ml BSA (nuclease-free)) 
- 10 µl nucleotide solution containing 0.5 mM dATP, 0.5 mM dGTP, 0.5 mM dCTP and 0.1 mM dTTP. 
10 µl 0.4 mM biotin-16-dUTP (or digoxigenein-11-dUTP or fluorescein-12-dUTP, all from Boehringer Mannheim) 
- 10 µl 100 mM DTT 
- 10 µl DNase I (Boehringer, for grade I a 1/100 dilution from a 1 mg/ml stock solution, for grade II a 1/666 dilution) 
- 6 µl DNA polymerase I (5 U/µl) (Boehringer). 
- X µl H2O to a final volume of 100 µl. 
Incubate at 16°C for 2 hours. 
Keep the reaction on ice. 
 
For two-colour in situ hybridisation one probe is labelled with Biotin-16-dUTP and the other is labelled with 
Digoxigenin-11-dUTP. 
 
II) Size check of the probe 
Take a 10 µl aliquot from the labelling reaction and add gel-loading buffer. 
Denature the aliquot by incubation in a boiling water bath for 2 min. 
Put the tube on ice for 2 min. 
Load the aliquot on a standard 1% agarose minigel (ethidium bromide free!) along with suitable size marker, as 
quickly as possible (to avoid probe renaturation). 
Run the gel at high voltage (e.g. 15 Volts per cm for 30 min.) to avoid probe renaturation in the gel. 
Visualize DNA by staining the gel in 0.5 µg/ml ehtidium bromide and take a picture. 
The probe molecule should be visible as a smear. This should contain only fragments smaller than 500 nt and larger 
than 100 nt. A peak intensity at 250-300 nt is optimal. 
If the probe DNA is between 100-500 nt, proceed with inactivation. 
If the probe is larger, add more DNase I to the reaction kept on ice, incubate further at 16°C (usually higher 
concentrations of DNase are added for a further 30 min. incubation). If the probe is smaller than 100 nt. Repeat the 
labelling reaction with less volume of DNase I dilution. 
Check the probe size again as described before. 
For enzyme inactivation incubate the labelling reaction at 65°C for 15 min. 
Store the probe at -20°C. 
 
III) Slide preparation 
Colchicine treated blood cultures are treated with a hypotonic solution containing 75 mM KCL (10-30 min., 37°C), 
followed by a methanol/acetic acid (3:1) fixation (3-4 times). The metaphase suspension is dropped on 
ethanol/diethyl-ether (1:1) cleaned, cold wet slides, and rinsed briefly with 70% acetic acid for the removal of 
cytoplasm. After overnight drying at room temperature (RT) the slides are stores dry at 4°C. 
 
IV) RNase treatment 
The slides are first washed twice 15 min. with PBS and then treated with 100 µg/ml RNase A (Boehringer) in 
2*SSC, 1 hour at 37°C (100 µl under a 24 x 50 mm cover slip, or in a coplin jar). After 3 x 5 min. washes with 
2*SSC this treatment can be followed by either a postfixation or a pepsin digestion and a postfixation. 
 
V) Pepsin digestion 
Wash the slides in pre-warmed PBS for 5 min. at 37°C and incubate them in pepsin solution (5 mg pepsin in 100 ml 
10 mM HCl) for 5 min. at 37°C. The slides are then washed in PBS for 5 min. at RT. A postfixation is performed in 
1% acid-free formaldehyde/PBS/50 mM MgCl2 pH 7, for 10 min. at RT. After one wash with PBS the slides are then 
dehydrated through a series of ethanol (70%, 90% and 100% 5 min. each) and air-dried. 
 
 34
VI) Hybridisation 
The hybridisation mix is made in the following way (for 1 hybridisation): 
For cosmids: 
1 µg competitor Cot-1 DNA (Gibco BRL) (or 5µg human DNA sonicated to a length of about 500 bp), 1 µg salmon 
sperm DNA, 1 µg yeast tRNA and 60-80 ng of the labelled probe. 
 
The DNA is then precipitated with 1/100 volume of 3 M NaOAC pH 5.6 and an equal volume of 2-propanol, spun 
down for 10 min. at 12K and washed with 70% ethanol. The pellet is dissolved in 10 µl hybmix (10% dextran 
sulfate/2*SSC/50% deionized formamide, pH 7). Probe and competitor DNA are denatured at 75°C for 5 min. A pre-
annealing (CISS, Chromosomal In Situ Suppression) is performed for cosmids at 37°C for 15-60 min. The probe 
DNA is kept on ice (not more than 5 min.) before applying it to denatured chromosomes. 
 
Denaturing of the chromosomes is started at least 30 min. before hybridisation. The denaturing is done by immersion 
of the slides in 70% formamide/2*SSC, pH 7, at 75°C for 5 min. After the denaturing the slides are quickly placed in 
pre-chilled (-20°C) 70% ethanol solution and kept in this solution until all the slides are denatured. The slides are 
then dehydrated through a series of cold 90%, 100% ethanol and air-dried. 10µl hybmix is placed without bubbles 
onto the slide and a 18 * 18 mm coverslip is lowered gently onto the droplet. The coverslip is sealed with rubber 
cement. The hybridisation is carried in a moist chamber (containing 2*SSC/50% overnight at 37°C. 
 
For two-colour in situ hybridisation the procedure is almost the same as described for one-colour hybridisation 
except that the two probes are dissolved in hybmix at a higher concentration and denatured separately. The biotin-
labelled probe and the digoxigenin-labelled probe are then mixed together (after pre-annealing if required), adjusted 
to a final volume of 10 µl with hybmix and placed on the denatured slide as above. 
 
VIII) Post-hybridisation steps 
- 3 times 5 min. washes in 50% formamide/2*SSC, pH 7 at 42°C. 
- 3 x 3 min. washes in 0.1*SSC, pH 7, 60°C. 
- 1 x 3 min. 4*SSC/0.05% Tween-20,pH /, at RT. 
- 10 min. preincubation with 4*SSC/0.05% Tween-20 containing 5% NFDM in a moist chamber (100 µl under a 24 
x 50 mm coverslip). 
- 20 min. incubation at RT with Avidin-Rhodamine (Vector Laboratories) (100 µl at 20 µg/ml in 4*SSC/5% 
NFDM/0.05% Tween-20 under a 24 * 50 mm coverslip). 
- 2 * 3 min. 4*SSC/0.05% Tween-20 at RT. 
- 1 * 3 min. 0.1 M Tris/HCl pH 7.570.15 M NaCl/0.05% Tween-20 (AbBB) at RT. 
- 30 min. incubation at 37°C with Biotinylated-goat-anti-Avidin (5 µg/ml) and monoclonal anti-Digoxinenin-FITC 
(Boehringer) (0.4 µg/ml) in AbBB/1% blocking reagent (Boehringer) (100 µl under a 24 * 50 mm coverslip). 
- 3 x 3 min. AbBB at RT. 
- 30 min. incubation at 37°C with Avidin-Rhodamine (20 µg/ml) 
- 2 x 3 min. AbBB at RT. 
- 2 x 5 min., PBS at RT. 
- The slides are mounted in antifade medium as described before, without propidium iodide. 
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